# Alzheimer's disease research and therapeutic developments

> Live situation record from CLSTR: https://clstr.news/situations/alzheimers-disease-research-and-therapeutic-developments
> Updated: 2026-08-25T02:09:09.000Z. Sources: 8. Developments: 2.

Scientific research into Alzheimer’s disease has focused on various biological mechanisms and the efficacy of different therapeutic approaches. Investigations have explored the possibility that the disease could spread through infection-like mechanisms, specifically examining whether amyloid-beta proteins might be transmitted via medical procedures such as blood transfusions.

A review published in The Lancet has examined the hypothesis that amyloid-beta proteins might behave similarly to infectious pathogens. This follows a 2023 study from Denmark and Sweden involving over one million people, which found that recipients of blood from donors who later developed cerebral hemorrhages faced a higher risk of similar brain bleeds years later. This risk is linked to cerebral amyloid angiopathy, a condition associated with amyloid-beta proteins.

While the presence of amyloid-beta ‘seeds’ in the blood is considered a biologically plausible explanation, experts emphasize that there is currently insufficient evidence to prove that blood transfusions are a common route of transmission or that the disease is contagious. Neurologists note that while research is vital for ensuring transfusion safety, further studies are required to establish a causal relationship.

Other research has identified potential preventative measures and treatment challenges. Studies involving postmenopausal women in the United Kingdom suggest that hormone replacement therapy (HRT) may reduce the risk of dementia and Alzheimer’s. Concurrently, researchers have identified gaps in current treatment protocols, noting that patients with atypical symptoms—such as impairments in language or vision—may be excluded from eligibility for existing anti-amyloid therapies. Additionally, neuroscientific findings have highlighted the role of the Neurofilament Light Chain (NEFL) protein, suggesting that reducing its levels could improve cognitive and motor functions.

## Timeline

### 2026-08-25: Alzheimer's research identifies gaps in therapy eligibility and protein mechanisms

Research suggests current anti-amyloid Alzheimer's therapies may exclude patients with atypical symptoms, while new studies explore NEFL protein reduction to improve cognitive function.

4 sources. https://clstr.news/cluster/alzheimers-research-identifies-gaps-in-therapy-eligibility-and-protein-mechanisms

### 2026-08-25: Alzheimer's proteins potentially transmissible via blood transfusions

Scientists are reviewing evidence to determine if amyloid-beta proteins associated with Alzheimer's could potentially be transmitted via blood transfusions, though no causal link is yet proven.

4 sources. https://clstr.news/cluster/alzheimers-research-examines-protein-transmission-and-hormone-therapy-benefits

---
Cite as: Alzheimer's disease research and therapeutic developments. CLSTR, https://clstr.news/situations/alzheimers-disease-research-and-therapeutic-developments